Headlines about Marrone Bio Innovations (NASDAQ:MBII) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media stories about the basic materials company an impact score of 46.1666798140634 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Marrone Bio Innovations (MBII) traded up $0.01 during trading on Tuesday, hitting $0.94. 78,300 shares of the company traded hands, compared to its average volume of 82,510. The company has a debt-to-equity ratio of -1.63, a quick ratio of 0.98 and a current ratio of 1.37. Marrone Bio Innovations has a 12 month low of $0.85 and a 12 month high of $2.61.
Marrone Bio Innovations (NASDAQ:MBII) last announced its quarterly earnings results on Monday, August 14th. The basic materials company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The company had revenue of $6.48 million for the quarter, compared to the consensus estimate of $6.62 million. equities research analysts forecast that Marrone Bio Innovations will post -1.05 EPS for the current year.
Several equities analysts have recently commented on MBII shares. HC Wainwright set a $4.00 target price on shares of Marrone Bio Innovations and gave the company a “buy” rating in a research report on Tuesday, August 15th. ValuEngine upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Piper Jaffray Companies set a $1.00 target price on shares of Marrone Bio Innovations and gave the company a “hold” rating in a research report on Saturday, July 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $2.50.
COPYRIGHT VIOLATION WARNING: This article was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2017/11/15/marrone-bio-innovations-mbii-receiving-somewhat-favorable-media-coverage-analysis-shows.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.